Abstract | The potent immunosuppressive action of rapamycin is commonly ascribed to inhibition of growth factor-induced T cell proliferation. However, it is now evident that the serine/threonine protein kinase mammalian target of rapamycin (mTOR) has an important role in the modulation of both innate and adaptive immune responses. mTOR regulates diverse functions of professional antigen-presenting cells, such as dendritic cells (DCs), and has important roles in the activation of effector T cells and the function and proliferation of regulatory T cells. In this Review, we discuss our current understanding of the mTOR pathway and the consequences of mTOR inhibition, both in DCs and T cells, including new data on the regulation of forkhead box P3 expression.
Rapamycin was isolated in the early 1970s from a soil sample obtained on Easter Island (Rapa Nui) and was identified as a potent antifungal metabolite 1 . This macrolide, which is produced by Streptomyces hygroscopicus, was found to inhibit cell proliferation and to have potent immunosuppressive activity. It is currently used for the prevention of kidney transplant rejec tion 2 . Rapamycin and its derivatives are also undergo ing clinical testing for prophylaxis of graft rejection 3 and graft-versus-host disease (GVHD) 4 , chemotherapy of some cancers 5 and the prevention of restenosis following angioplasty 6 . Our understanding of the mechanisms that underlie the unique immunosuppressive profile of rapamycin continues to evolve. In line with this, the central and pervasive role of the serine/threonine protein kinase mammalian target of rapamycin (mTOR) in innate and adaptive immune responses is becoming appar ent. Blockade of mTOR by rapamycin impairs dendritic cell (DC) maturation and function and inhibits T cell proliferation, a mechanism that underpins its immuno suppressive effect. There is now strong evidence that mTOR is crucial for the regulation of antigen respon siveness in CD4 + T cells. This effect seems to be medi ated by an influence of mTOR inhibition on naturally occurring regulatory T (T Reg ) cells, which have a key role in immunological tolerance. Exciting information has emerged regarding the role of the phosphoinositide 3kinase (PI3K)-AKT-mTOR pathway in regulat ing DC and T cell function, particularly in relation to the expression of forkhead box P3 (FOXP3) and the differentiation of T Reg cells. In this Review, we discuss the remarkable recent progress in the elucidation of the mechanisms by which mTOR inhibition affects intracellular signalling pathways in immune cells, par ticularly in DCs and T cells, and how this influences immune responses.
The mTOR signalling pathway Discovery of mTOR. Genetic screening of Saccharomyces cerevisiae identified two TOR genes (TOR1 and TOR2) and gave an early indication of the importance of TOR in the control of cell proliferation 7 . The function of TOR proteins was found to be inhibited by rapamycin in a com plex with the immunophilin FK506binding protein 1A, 12 kDa (FKBP12) 8 
. A single mTOR gene was then identified in rat, mouse and human cells, which had a high degree of homology to yeast TOR genes [9] [10] [11] . Subsequent work has identified mTOR as an atypical serine/threonine protein kinase with a central role in mammalian development 12, 13 . It is a crucial regulator of cell growth and proliferation, and of physiological events such as transcription, mRNA turnover and translation, ribosomal biogenesis, vesicular trafficking, autophagy, cytoskeletal organization and cell size 14 . mTOR exists in at least two complexes, mTOR com plex 1 (mTORC1) and mTORC2 (BOX 1) , that have dis tinct relationships both to upstream and downstream effectors and to each other (FIG. 1) . Indeed, mTOR in mTORC1 is highly sensitive to inhibition by rapamycin, whereas mTOR in mTORC2 is resistant to rapamycin; the reason for this is unknown. Notably, rapamycin insensitive functions of mTORC1 in mouse embry onic fibroblasts have been identified recently using Graft-versus-host disease (GVHD) . A disease that results from immunological attack by donor allogeneic T cells transferred with the allograft (such as bone marrow, liver or gut) of target recipient organs or tissues (such as skin or gut). GVHD occurs in graft recipients who cannot eliminate the host-reactive donor T cells owing to immunosuppression, immunological immaturity or tolerance of the recipient.
Immunophilin
A peptidyl-prolyl isomerase that is targeted by certain immunosuppressive drugs (such as cyclosporin A, FK506 and rapamycin). The drug-immunophilin complex is responsible for the immunosuppressive action of the drug.
Autophagy
A tightly regulated catabolic process that involves degradation of the cell's own intracellular components through the lysosomal machinery and is a normal part of cell growth, development and homeostasis.
Small interfering RNA
A class of 20-25-nucleotide long double-stranded RNA molecules that are involved in the RNA interference pathway, which interferes with the expression of a specific gene. Also known as silencing RNA.
a new inhibitor (known as Torin 1) of both mTORC1 and mTORC2 (ReF. 15) . Also, prolonged exposure to rapamycin can impede the assembly of mTORC2 in some cells 5, 16, 17 .
Signalling through mTORC1. In immune cells, mTORC1 is a regulator of cell growth and other processes down stream of PI3K-AKT, WNT-GSK3 (glycogen synthase kinase 3) and AmPactivated protein kinase (AmPK) signalling (FIG. 1) . Details of mTORC1 signalling can be found in recent comprehensive reviews 14, 18, 19 . Tuberous sclerosis complex 1 (TSC1) and TSC2 together form a functional complex that acts as the upstream inhibitor of mTORC1. Growth factors, cytokines, costimulatory molecules and antigen receptors activate PI3K, which subsequently activates AKT. Fully activated AKT inhibits TSC2 by phosphorylating it 20 , thereby negating the inhibitory effect of TSC2 on mTORC1. Activation of the RAS-mAPK (mitogenactivated protein kinase) pathway also leads to inhibition of the TSC1-TSC2 complex 14 . Alternatively, cellular stress and DNA damage can inhibit mTORC1 by promoting the regulatory capacity of TSC1-TSC2 (ReFs 14, 19) . The inhibitory activity of the TSC1-TSC2 complex is mediated by inhibiting RHEB (RAS homologue enriched in brain), a RASlike GTPase and a positive regulator of mTORC1 (ReFs 18, 19) .
Removal of mTORC1 inhibition allows mTORC1 to phosporylate S6 kinase 1 (S6K1; also known as RPS6KB1) and the eukaryotic initiation factor EIF4EBP1 (eukaryotic translation initiation factor (EIF4E)binding protein 1). Phosphorylated S6K1 promotes mRNA translation and cell growth by enhancing the biosyn thesis of the translational apparatus in the cell 14, 19 . The phosphorylation of EIF4EBP1 prevents it from inhibiting EIF4E, which also stimulates translation 14 . WNT proteins bind to the Frizzled family of recep tors, which are involved in the regulation of effector T cell development, T Reg cell activation and DC matu ration 21 . The WNT pathway influences the mTORC1 pathway by inhibiting GSK3, which in the absence of WNT signalling is an additional negative regulator of mTORC1 (ReF. 22) .
Signalling through mTORC2. Knowledge of the more recently defined mTORC2 is limited compared with mTORC1 because of the lack of an mTORC2specific inhibitor. Studies targeting RICTOR (rapamycin insensitive companion of mTOR; a defining com ponent of mTORC2) (BOX 1) through small interfering RNA 23, 24 and studies of Rictorknockout mice 13 have shown the importance of mTORC2 in mammalian development and several cellular processes. mTORC2 mediated phosphorylation of AKT is stimulated by insulin and can be blocked by PI3K inhibitors 25 . However, knockdown of Rictor does not decrease S6K1 activation 24 , indicating that mTORC2 does not activate mTORC1 (ReF. 24) .
Targeting Rictor has also established that mTORC2 regulates the actin cytoskeleton through the small GTPase RAS homologue (RHO) and protein kinase C 14 . The TSC1-TSC2 complex has been shown to regulate cell adhesion and migration 26 , but it is not clear whether it sig nals to and regulates mTORC2 directly. Regulation of cell movement and adhesion is an important feature of effec tive immune responses, so it is possible that mTORC2 might also be shown to modulate immune reactivity when specific inhibitors become available.
S6K1-mediated regulation of mTOR signalling. mTOR is a crucial coordinator of signalling pathways, so it is not surprising that feedback inhibition is an important component of the pathway. Activated S6K1, the main effector of uninhibited mTORC1, negatively regu lates input from the PI3K-AKT signalling pathway to mTORC1 (ReFs 19, (27) (28) (29) by phosphorylating and ini tiating the degradation of insulin receptor substrate 1 (IRS1), which is the molecular intermediate between insulin receptor and PI3K 19, [27] [28] [29] [30] [31] . It has not been deter mined whether S6K1 can also negatively regulate input from other receptor systems that activate mTOR through PI3K. Activated S6K1 can also positively regu late mTOR activation. GSK3, which is constitutively activated in the absence of growth factors, negatively regulates the mTOR pathway by stimulating the TSC1-TSC2 complex. under certain conditions, activation of S6K1 can negatively regulate GSK3 (ReFs 32, 33) , thus facilitating cell proliferation. 14, 18, 19 . Also consistent with other PIKKs, mTOR contains a FRAP-ATM-TTRAP (FAT) domain and a C-terminal FAT (FATC) domain that might have a role in its structure and stability 134 (see the figure). Mammalian LST8 (also known as GβL) associates with the kinase domain of mTOR and is thought to facilitate mTOR signalling, but its precise role has yet to be defined 135, 136 . In addition, mTOR seems to be involved in various protein-protein interactions that determine its physiological role. It has been established that mTOR exists in at least two distinct complexes, mTOR complex 1 (mTORC1) and mTORC2. mTOR and LST8, together with the regulatory associated protein of mTOR (RAPTOR) form mTORC1. RAPTOR is essential for mTORC1 activity and is proposed to interact with mTOR through shared HEAT domains 19 . Rapamycin binds to the immunophilin FK506-binding protein 1A, 12 kDA (FKBP12) to form a drug-receptor complex that specifically and effectively blocks the activity of mTORC1. The rapamycin-FKBP12 complex binds next to the kinase region of mTOR in the FKBP12-rapamycin-binding (FRB) domain 136 and disrupts the in vitro and in vivo activity of the complex, potentially by disrupting the interaction between RAPTOR and mTOR 14 . mTORC2 also contains LST8, but instead of RAPTOR, it associates with rapamycin-insensitive companion of mTOR (RICTOR) and possibly MAPKAP1 (mitogen-activated protein kinase-associated protein 1; also known as SIN1) 19, 137 . Unlike mTORC1, mTORC2 is resistant to direct inhibition by rapamycin. It is unknown what prevents the interaction between the rapamycin-FKBP12 complex and the FRB domain on mTORC2 (ReF. 14) . Nature Reviews | Immunology 
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Overall, the mTOR kinase, functioning in mTORC1 and mTORC2, acts as a coordinator of signalling path ways that shape the response of cells to various stimuli. Immune cells, using receptors that signal through mTOR directly or indirectly, modulate host responses based on their 'perception' of environmental danger. We focus here on the role of mTOR in DCs and T cells, but it is worth noting that the inhibition of mTOR by rapamycin has effects on other immune cells (BOX 2) that are outside the scope of this Review. 34 . An early study suggested that rapamycin did not affect the phe notypic differentiation or CD40linduced maturation of human monocytederived DCs in vitro, but instead pro moted apoptosis of these DCs and of CD34 + precursor cellderived DCs 35 . By contrast, studies of mouse bone marrowderived DCs 34 showed that mTOR inhibition suppressed interleukin4 (Il4)dependent maturation through the posttranscriptional downregulation of the Il4 receptor (Il4R) complex. In this case, rapamycin inhibited the expression of costimulatory molecules by DCs both in vitro and in vivo and suppressed their Il4 induced production of Il12 and tumour necrosis fac tor (TNF) as well as their T cell stimulatory function 34 . Further work has shown that mTOR inhibition during DC differentiation inhibits the upregulation of CD86 expression that is induced by Tolllike receptor (TlR) ligands (such as lipopolysaccharide (lPS) or CpG DNA) or by a CD40specific monoclonal antibody 36 . mTOR inhibition also decreases the production of nitric oxide by lPSstimulated macrophages 37 , an effect that is due in part to impaired secretion of interferonβ (IFNβ), which is an autocrine cofactor for nitric oxide produc tion. Furthermore, the inactivation of mTOR decreases the secretion of Il2 by DCs following their stimula tion through the Ctype lectin receptor dectin 1 (also known as ClEC7A) 38 , indicating that cytokine produc tion through the activation of Ctype lectin receptors involves mTOR.
Immature DCs undergo differentiation in response to hypoxia and they overexpress hypoxiainducible factor 1α (HIF1α) and its downstream target genes, including vascular endothelial growth factor and glucose transporter 1 (ReF. 39) . mTOR inhibition attenuates these responses, and rapamycin can suppress hypoxiainduced inflammation by inhibiting the HIF1α pathway 39 . All of these observations relate to the effects of soluble rapamy cin; however, there are recent reports that the delivery of rapamycin through biodegradable nanoparticles or microparticles enhances its inhibitory effects on the maturation and T cell stimulatory function of mouse and human DCs [40] [41] [42] . Antigen uptake and presentation. DCs use several pathways for antigen uptake: phagocytosis, constitu tive macropinocytosis and mannose receptormediated endocytosis. Rapamycin impairs macropinocytosis and These signals all mediate their effects through the tuberous sclerosis complex 1 (TsC1)-TsC2 complex, which is the main negative regulator of mTORC1. Activation of RAs-MAPK (mitogen-activated protein kinase) and phosphoinositide 3-kinase (PI3K)-AKT signalling results in inhibitory phosphorylation of TsC2 and removes repression of RHeB (RAs homologue enriched in brain), which is the mTORC1 stimulator. Activation of PI3K-AKT signalling is negatively regulated by phosphatase and tensin homologue (PTeN). Activated mTORC1 promotes mRNA translation by stimulating s6 kinase 1 (s6K1; also known as RPs6KB1) and inhibiting eIF4eBP1 (eukaryotic translation initiation factor-binding protein 1). Activated s6K1 can also feed back to negatively regulate input from PI3K-AKT by facilitating the degradation of signalling intermediates between surface receptors (such as the insulin receptor) and PI3K. Low energy and nutrient levels (signalling through AMP-activated protein kinase; AMPK), as well as hypoxic conditions, increase the TsC1-TsC2-mediated inhibition of mTORC1 that is downstream of input from glycogen synthase kinase 3 (GsK3). mTORC2 is not inhibited directly by rapamycin, but long-term rapamycin administration disrupts its assembly in some cells. mTORC2, activated by PI3K, directly phosphorylates AKT. mTORC2 also regulates actin cytoskeletal dynamics through the small GTPase RAs homologue (RHO) and protein kinase C (PKC). PDK1, phosphoinositide-dependent kinase 1. endocytosis of antigens by cultured mouse immature bone marrowderived DCs 43 . Rapamycin also inhibits endocytosis in vivo in mouse splenic DCs 34 . Human monocytederived DCs that have differentiated in the presence of rapamycin have decreased expression of antigen uptake receptors (such as CD32, CD46, CD91 and CD205) and decreased receptormediated and fluidphase endocytosis and phagocytosis of bacteria and apoptotic cells 44 (FIG. 2a) . Although the mechanisms by which rapamycin inhibits endocytosis are unclear, the inhibition of mTOR by shortterm exposure to rapamycin abolishes the translation of RHO-associated coiledcoilcontaining protein kinase 1 (ROCK1) in mouse macrophages, which results in the inhibition of phagocytosis and chemotaxis 45 . unlike calcineurin inhibitors (such as cyclosporin A and FK506), rapamycin does not inhibit the presen tation of mHCrestricted antigens (such as ovalbu min) or of minor histocompatibility antigens to T cells by mouse bone marrowderived DCs [46] [47] [48] . This might be because calcineurin inhibitors have inhibitory effects on the early stages of DCinduced activation of naive T cells (such as cytokine production), whereas rapamycin inhibits later stages. There is, however, recent evidence that mTOR inhibition can suppress the transient aggregation of ubiquitylated cytoplas mic proteins during lPSinduced DC maturation 49, 50 . These aggresomes, which in DCs are known as DC aggresomelike structures (DAlIS) (FIG. 2a) , might function as depots of antigen that can be cross presented by mHC class I molecules and might allow DCs to coordinate their maturation and antigen presenting functions while they migrate from the periphery to secondary lymphoid tissues.
Crosspresentation of antigen is essential for the generation of cytotoxic T cell responses against cer tain tumour cells and viruses. The fact that calcineurin inhibitors, but not rapamycin, inhibit the cross presentation of an exogenous antigen by mouse DCs 47 might explain why in mice bearing an allograft and a tumour, cyclosporin A inhibits allograft rejection but promotes tumour growth (through inhibiting the cross presentation of tumourspecific antigens), whereas rapamycin suppresses both processes 51 . Autophagy is a constitutive process in DCs 52 in which autophagosomes sequester intracellular contents (such as damaged organelles and macromolecules) and target them for lysosomal degradation. This process is thought to be involved in the mHC class II antigen presentation pathway that leads to self tolerance and in innate and adaptive immune responses 53, 54 . TOR1 and TOR2 are involved in the repression of autophagy in Saccharomyces cerevisiae 55 . Rapamycin induces autophagy in yeast 56 and also in mouse macrophages and mouse DCs, thereby enhancing their antigenpresenting ability 57 . Further studies are required to determine the extent to which autophagy influences the peptide-mHC class II reper toire and how this might be affected by mTOR inhibition. Overall, rapamycin can interfere with antigen uptake by DCs and can modulate events that are associated with antigen presentation, although the mechanistic basis of these effects requires clarification. DC survival. DC survival is important for the induc tion of immune responses, for example to viruses and tumours 35, 58 . Blocking of granulocyte/macrophage colony stimulating factor (GmCSF) signalling by rapamycin induced the apoptosis of both human monocytederived DCs and DCs derived from CD34 + precursor cells, but not of monocytes or macrophages. By contrast, the frequency of apoptotic or dead cells was consistently lower than 10% in rapamycinconditioned, bone marrowderived mouse DC cultures and in vivogenerated DCs from rapamycin treated mice 34 . As pointed out by these authors, pro and antiapoptotic effects of rapamycin have been reported for different cell types, possibly reflecting the differen tial sensitivity of mTORC2 to disruption in these cells. Interestingly, no increase in cell death was observed fol lowing mTOR inhibition by rapamycin in virusinfected, FlT3lderived DCs 38 .
Box 2 | mTOR inhibition affects B cells, NK cells, neutrophils and mast cells
In addition to its influence on antigen-presenting cells and T cells, rapamycin has direct effects on other immune cells that impair their proliferation and function. Mammalian target of rapamycin (mTOR) inhibition thus has a broad range of inhibitory effects on immune effector cells.
B cells
Phosphoinositide 3-kinase (PI3K) and mTOR are required for B cell proliferation. Early and late B cell receptor (BCR) signals are blocked by mTOR inhibition 138 . For example, rapamycin inhibits BCR-induced S6 kinase 1 (S6K1; also known as RPS6KB1) activation and DNA synthesis in mouse B cells 139 . B cell responses to lipopolysaccharide are also sensitive to rapamycin 140 . In addition, mTOR inhibition suppresses mouse splenic B cell activation through CD40 (ReF. 141) , resulting in decreased proliferation and differentiation to IgM hi IgD low cells. Rapamycin inhibits CD40-specific antibody-mediated prevention of apoptosis that is induced by BCR cross-linking and suppresses human B cell proliferation after CD40 ligation in the presence of B cell-activating cytokines (which is accompanied by increased apoptosis) 142 . Moreover, rapamycin potently inhibits the number of IgM-producing and, to a lesser extent, IgG-producing B cells. When Staphylococcus aureus and CD40 ligand are used as stimulants, rapamycin decreases interleukin-2 (IL-2)-dependent and IL-2-independent human B cell proliferation, as well as IL-2-dependent differentiation to antibody-secreting cells 143 . Rapamycin also suppresses cytokine-induced proliferative responses and IgM production by pre-activated human B cells 144 .
natural killer cells
Rapamycin inhibits the proliferation of rat primary natural killer (NK) cells and of the RNK-16 NK cell line by blocking the progression from G1 to S phase of the cell cycle 145 . However, rapamycin does not affect interferon-γ secretion by primary NK cell lines. NK cell-mediated killing of conventional YAC-1 T cell lymphoma target cells is modestly decreased by mTOR inhibition. In vivo, rapamycin administration decreases the number of circulating NK cells in rat liver allograft recipients 145 but does not seem to influence NK cell cytotoxic activity in rats receiving hamster skin xenografts 146 . neutrophils Rapamycin potently suppresses human neutrophil chemotaxis and chemokinesis elicited by granulocyte/macrophage colony-stimulating factor (GM-CSF), and inhibits responses to IL-8 (ReFs 147, 148) . Rapamycin inhibits the increase in S6K1 activity induced by GM-CSF, as well as GM-CSF-induced actin polymerization, a marker of leukocyte migration. mTOR complex 1 participates in Toll-like receptor 2 (TLR2)-and TLR4-induced neutrophil activation and acute lung injury 149 .
mast cells
Rapamycin has little effect on histamine release from lung mast cells but it does antagonize the inhibitory effect of FK506 on anti-IgE-induced histamine release from human mast cells 150 .
IL-1β AKT mTORC2
Caspase 1 mTORC1 Figure 2 | mToR and rapamycin regulate APC function. a | several changes are observed in antigen acquisition and presentation by antigen-presenting cells (APCs) that are exposed to or differentiated in rapamycin. Rapamycin inhibits phagocytosis, endocytosis and pinocytosis, decreases the expression of antigen uptake receptors (such as CD46, CD91, CD32 and the mannose receptor) and MHC class II molecules and disrupts dendritic cell aggresome-like structures (DALIs). However, cross-presentation of exogenous antigen on MHC class I molecules does not seem to be affected. Rapamycin facilitates autophagy, an evolutionarily conserved process, and could thereby influence the presentation of self antigens. Thus, mammalian target of rapamycin (mTOR) has a role in the regulation of immune responses at an early stage, influencing how exogenous and endogenous antigen is acquired, processed and presented. b | Differentiation of dendritic cells (DCs) in rapamycin generates DCs with weak T cell stimulatory capacity but intact and enhanced homing to CC-chemokine ligand 19 (CCL19). mTOR complex 1 (mTORC1) is a negative regulator of caspase 1, and treatment with rapamycin (which binds the immunophilin FK506-binding protein 1A, 12 kDa (FKBP12)) therefore promotes interleukin-1β (IL-1β) production that is mediated by caspase 1. IL-1β subsequently induces expression of IL-1 receptor-like 1 (IL-1RL1; also known as sT2), which sequesters myeloid differentiation primary-response gene 88 (MyD88) and negatively regulates Toll-like receptor 4 (TLR4) signalling. Failure of rapamycin to impede AKT signalling downstream of cytokine receptors (such as the receptors for granulocyte/macrophage colony-stimulating factor (GM-CsF), IL-4 and FMs-related tyrosine kinase 3 ligand (FLT3L)) might increase the expression of CC-chemokine receptor 7 (CCR7) and therefore the migration of DCs in response to CCL19. c | Interruption of mTORC1 signalling in monocytes, macrophages and DCs during TLR ligation results in increased IL-12p40 production by decreasing IL-10 production and de-repressing nuclear factor-κB (NF-κB). This indicates that mTOR is a crucial mediator of T cell polarization and immune responses. d | In plasmacytoid DCs (pDCs), coordinated signalling through TLR9 and phosphoinositide 3-kinase (PI3K)-mTOR is needed to drive the production of type 1 interferons (IFNs). s6 kinase 1 (s6K1) phosphorylation by mTORC1 promotes the interaction of MyD88 with TLR9 and IFN regulatory factor 7 (IRF7) and the subsequent translocation of phosphorylated IRF7 to the nucleus to initiate transcription of the genes encoding type 1 IFNs. mTOR has been reported to interact with MyD88 and positively regulate cytokine production mediated by IRF5 and IRF7. LPs, lipopolysaccharide; GsK3, glycogen synthase kinase 3; sTAT3, signal transducer and activator of transcription. 
Calcineurin inhibitor
A complex of either cyclosporin A and cyclophilin, or FK506 and FKBP12, that inhibits the phosphatase activity of calcineurin. minor histocompatibility antigen An antigenic peptide derived from polymorphic cellular proteins (alloantigens) bound to mHC class I molecules that can cause rejection of mHC-matched grafts.
Aggresome
A proteinaceous inclusion body that forms (within dendritic cells and other cells) when the cell's degradation machinery is impaired or overwhelmed under stress and that sequesters potentially toxic aggregates for subsequent clearance. Dendritic cell aggresome-like structures are known as DAlIs.
DC migration. By increasing the expression of CCchemokine receptor 7 (CCR7), rapamycin increases the migration of human DCs in response to CCchemokine ligand 19 (CCl19) in vitro (FIG. 2b) and mouse DC migration to lymph nodes in vivo 59 . Similarly, functional expression of CCR7 is retained on rapamycin conditioned mouse DCs 36, 60 , which promotes their homing to secondary lymphoid tissue during inflamma tory responses following allogeneic haematopoietic cell transplantation 60 . Intact in vivo migration of syngeneic rapamycinconditioned DCs to secondary lymphoid tis sue has also been reported in a heart allograft model 61 . Retention of this in vivo migratory ability is probably crucial for the immunoregulatory properties that have been ascribed to rapamycinconditioned DCs, as it allows these cells to reach appropriate T cell areas in the lymphoid tissue.
Cytokine production by DCs and pDCs. The coordi nated secretion of pro and antiinflammatory cytokines is essential for effective immune responses 62 . An unex pected finding is that mTOR suppresses the activation of caspase 1 (the molecular basis of which is unclear) and therefore the production of bioactive Il1β 38 . mTOR inhibition elicits de novo production of Il1β by oth erwise phenotypically immature, mouse bone marrow derived DCs both in vitro and in vivo 63 . moreover, Il1β production by rapamycinconditioned DCs promotes overexpression of the transmembrane form of the Il1R family member, Il1Rlike 1 (Il1Rl1; also known as ST2) 63 (FIG. 2b) , which is the recently identified receptor for Il33 and promotes T helper 2 (T H 2) cell responses 64 . Il1Rl1 is also thought to be a potent negative regula tor of TlR signalling in macrophages 65 . (FIG. 2c) . Blocking mTOR increases Il12 production by lPSstimulated DCs, an effect that is mediated by inhib iting the autocrine secretion of Il10 (which normally inhibits Il12 production in a negative feedback mecha nism). Consistent with this observation, the activation of mTOR by the transduction of a constitutively active form of RHEB inhibits Il12 production. By contrast, GSK3 inhibition attenuates Il12 production but increases Il10 production by lPSstimulated DCs. In related studies, the activation of mTOR in mononuclear phagocytes increased the activity of signal transducer and activator of transcrip tion 3 (STAT3) and the production of Il10, but decreased the production of proinflammatory molecules (such as Il12) and the activation of nuclear factorκB (NFκB); mTOR inhibition had reciprocal effects 67 . Similarly, rapamycin increased Il12 production and decreased Il10 production by human DCs stimulated with lPS or Staphylococcus aureus 68 . Such findings imply that mTOR and GSK3 pathways might regulate the T H 1-T H 2 cell balance by modulating the production of Il10 and Il12 by DCs (FIG. 2c) . Rapamycintreated monocytes induce the polarization of T H 1 cells and T H 17 cells 68 , and rapamycin greatly increases the expression of Il12p40 (a shared component of Il12 and Il23; also known as Il12B) and the levels of IL23p19 (also known as IL23A) mRNA and Il23 protein in human macrophages infected with Mycobacterium tuberculosis 69 . Together, these observations identify the GSK3-mTOR pathway as a key regulator of immune homeostasis.
The mTOR pathway has recently been implicated in the regulation of production of type 1 IFNs (IFNα and IFNβ), which are crucial for antiviral immunity, by plasma cytoid DCs (pDCs) 70 . mTOR associates with mye loid differentiation primaryresponse gene 88 (myD88), an adaptor protein that is used by many TlRs, to allow the activation of IFN regulatory factor 5 (IRF5) and IRF7, which are transcription factors for type 1 IFN genes 38, 71 . Thus, inhibition of mTOR signalling during pDC activa tion through TlR9 blocks the interaction between TlR9 and myD88 and the subsequent phosphorylation and nuclear translocation of IRF7, resulting in impaired IFNα and IFNβ production 72 (FIG. 2d) . Decreased IFNα levels in the serum and decreased production of IFNα by pDCs in response to stimulation with CpG DNA or a viral vac cine lead to impaired adaptive CD8 + T cellmediated immune responses 72 . In summary, rapamycin exerts numerous effects on DC differentiation, maturation and function. It interferes with antigen uptake and might modulate antigen pres entation. Its differential effects on cytokine production and chemokine receptor expression regulate interactions between innate immune and adaptive T cell responses. mTOR in effector and regulatory T cells T cells have a fundamental role in host responses to invading pathogens and tumours. T Reg cells control the reactivity of effector T cells, and their important role is emphasized by the severe pathological conditions that are associated with T Reg cell deficiency 73 . As our understand ing of the fine balance between effector T cells and T Reg cells becomes clearer, the influence of mTOR inhibition on their activity is providing surprising insights.
Thymocyte development. In rodents, blocking mTOR activity causes marked thymic involution, which is asso ciated with decreased T cell output 74 . Recent reports have shown that prolonged rapamycin administration blocks the conversion of thymocytes from double negative (CD4 -CD8 -) to doublepositive T cells 75 . Although the absolute number of T cells is decreased, rapamycin administration does not alter the propor tion of CD4 + singlepositive cells that upregulate their expression of FOXP3 in the thymus 76 . This indicates Nature Reviews | Immunology signals that are necessary to pass the two checkpoints of T cell activation. The transition from G0 to G1 phase of the cell cycle (checkpoint 1) requires activation of nuclear factor of activated T cells (NFAT), mitogen-activated protein kinases (MAPKs), activator protein 1 (AP1) and nuclear factor-κB (NF-κB). The activity of NF-κB is controlled by the phosphoinositide 3-kinase (PI3K)-AKT-mTOR pathway. mTOR functions as part of the complexes mTORC1 and mTORC2, of which the former is susceptible to inhibition by rapamycin in complex with the immunophilin FK506-binding protein 1A, 12 kDa (FKBP12). The coordinated activity of NFAT, MAPKs, AP1 and NF-κB regulates the transcription of many genes that are involved in cell cycle progression as well as the expression of IL-2 and its high-affinity receptor, IL-2R. IL-2R signalling activates mTOR through the PI3K-AKT-mediated signalling pathway. mTOR then forms a complex with survivin and aurora B, and together they regulate G1 to s phase progression (checkpoint 2). In addition, mTOR is involved in rapamycin-sensitive downregulation of the transcription factor Kruppel-like factor 2 (KLF2), which controls the expression of lymphoid tissue-homing molecules (such as CD62L, CC-chemokine receptor 7 (CCR7) and sP1) to ensure that activated T cells can exit the lymph nodes. b | The ability of regulatory T (T Reg ) cells to proliferate when stimulated in the presence of rapamycin seems to be connected to two effects. First, T Reg cells do not downregulate phosphatase and tensin homologue (PTeN) expression after TCR engagement, which impedes the activation of the rapamycin-susceptible PI3K-AKT-mTOR pathway. second, forkhead box P3 (FOXP3) drives the expression of PIM2, reinforced by IL-2-and TCR-mediated activation of signal transducer and activator of transcription 5 (sTAT5); PIM2 compensates for AKT inactivity and promotes cell cycle progression. JAK, Janus kinase.
Two-signal T cell activation model
The concept that both the peptide-mHC complex (signal 1) and the co-stimulatory signals that are delivered by CD80 and CD86 expressed by antigenpresenting cells (signal 2) are required for T cell activation. Absence of signal 2 results in the induction of T cell anergy or deletion.
that the ontogeny of natural T Reg cells is unaffected by mTOR blockade. This is surprising in view of recent evidence that FOXP3 expression is negatively regulated by the PI3K-AKT-mTOR axis; thymocytes expressing a constitutively active form of AKT could not upregulate FOXP3 expression 77 . Thus, it might be expected that by blocking mTOR, a higher proportion of CD4 + cells would upregulate FOXP3. Absence of such an effect in the thy mus suggests that thymic T Reg cell generation is based on the initiation of a genetic programme 78 that is controlled by AKT signalling but is independent of mTOR activity.
T cell activation and anergy. T cell activation in the periphery is a complex process requiring progress through two main checkpoints (FIG. 3a) that limit entrance into the cell cycle 79 . The first checkpoint is progression from G0 to G1 phase of the cell cycle. Detailed analysis of the molecular processes that underlie the two-signal T cell activation model has shown that, in addition to T cell recep tor (TCR)driven activation of nuclear factor of activated T cells (NFAT) and mAPK, integration of both TCR and CD28 signals is required for PI3K and AKT activa tion. As discussed earlier, mTOR is a target of AKT and, through its activity in the mTORC1 and mTORC2 com plexes, it can stimulate four pivotal processes that regulate progression from G0 to G1 phase. These are increased mRNA translation, increased glycolysis and consequent ATP accumulation, degradation of the cyclindependent kinase (CDK) inhibitor p27 (also known as KIP1) and promotion of Il2 and Il2R expression (together with the transcriptional regulators NFAT and activator protein 1). The increase in protein production as a result of mTOR activity allows the T cells to reach the mass that is needed for successful division, a process that requires the energy made available through the increased produc tion of ATP. Initial progression from G0 to G1 phase is then regulated by the activity of CDK proteins, which drive the cell to the second checkpoint, the transition from the G1 to S phase of the cell cycle. Successful pro gression through this transition requires sustained stimu lation through TCR and CD28, together with autocrine signalling by Il2 produced during progression through the first checkpoint. The PI3K-AKT-mTOR pathway is also involved in transmission of this Il2R signal 79 . It now seems that mTOR activity at this phase of the cell cycle is in the form of a new complex with the proteins survivin (an inhibitor of apoptosis family protein; also known as BIRC5) and aurora B (a serine/threonine pro tein kinase) 80 . The expression and activity of both sur vivin and aurora B depends on CD28 stimulation and Il2mediated signalling. The target specificity of the mTOR-survivin-aurora B complex is similar to that of mTORC1, with an additional aurora Bregulated capac ity to control retinoblastoma phosphorylation, cyclin A expression and CDK1 and CDK2 activity, all of which are involved in G1 to S phase progression 79 . Interestingly, similarly to mTORC1, this new mTOR complex is susceptible to inhibition by rapamycin.
An additional immunosuppressive effect of mTOR blockade during T cell activation has been recently iden tified. Il2-Il2R signalling in differentiating effector T cells results in downregulation of the transcription factor Kruppellike factor 2 (KlF2), which controls the expression of the homing molecules SP1, CD62l, CCR7 and other chemokine receptors. This decrease in KlF2 levels depends on PI3K activation and involves mTOR activation 81 . The presence of rapamycin during Il2mediated signalling prevents the downregulation of KlF2 and, consequently, the modulation of expression of SP1, CD62l and CCR7 that is necessary for the egress of effector T cells from lymph nodes. So, in addition to blocking cell cycle progression during T cell activation, rapamycinmediated mTOR inhibition could sequester activated T cells in lymphoid tissues and prevent them from reaching the target tissue. mTOR activation is a key process in preventing T cell anergy. Treatment of antigenstimulated T cells with rapamycin slows cell cycle progression to the G1 phase and prevents the downregulation of genes that are involved in the development of anergy 82 . In addition, it is now clear that Il2-Il2R signalling has a direct role in preventing anergy 83 . An excess of Il2 can reverse anergy through an mTORdependent, rapamycin sensitive signalling pathway 84, 85 . These observations sup port the view that proanergy factors are induced early after TCR stimulation and are subsequently degraded or suppressed in response to Il2R signalling. This indicates that conventional mTORC1 activity is necessary for T cell activation but is insufficient to reverse the programme of anergy induction. A separate, Il2specific signalling event is required during the G1 phase to preserve antigen responsiveness and might involve the mTOR-survivinaurora B complex. The activity of this complex could underlie the recent observations regarding the involve ment of the PI3K-AKT-mTOR axis in the induction of FOXP3 expression in the periphery (see below).
Rapamycin is most effective at preventing T cell divi sion under conditions of low Il2 availability 79 . In the pres ence of optimal autocrine Il2 secretion or of exogenous Il2, rapamycin delays but cannot prevent cell division 86 . This alternative regulation of late cell cycle progression by Il2 seems to depend on the recently discovered STAT5 dependent expression and activity of the serine/threonine protein kinase PIm2 (ReF. 87) . PIm2 can maintain nutri ent uptake and ATP synthesis at high levels and, similarly to AKT, regulates cell survival during blastogenesis. So, mTORinduced signalling might regulate the rate of initial cell cycle entry and the integration of sequential signals that are dictated by TCR and CD28 engagement and Il2 production, but it becomes dispensable at later stages, when large quantities of Il2 are available 86 .
T Reg cell homeostasis, function and proliferation.
Rapamycin does not affect the function and homeo stasis of T Reg cells to the same extent as conventional T cells, as recently reviewed 88 . In vitro exposure of mouse or human T Reg cells to rapamycin does not impair their ability to suppress effector T cell proliferation 89 , an effect that is lost when the calcineurin inhibitor cyclosporin A is used 90, 91 . In addition, prolonged in vivo administra tion of rapamycin results in a pronounced increase in the number of T Reg cells compared with CD4
+ T cells in all lymphoid organs, although the absolute numbers of all T cells are decreased (similarly to the thymus) 76, 92 . A sim ilar finding has been made in kidney transplant recipi ents 92, 93 ; patients treated with rapamycin have a markedly increased frequency of CD4 + CD25 + FOXP3 + T Reg cells compared with total CD4 + T cell numbers. This effect is reversed in patients treated with calcineurin inhibitors. In a TCRtransgenic mouse model, rapamycin was used in vitro in combination with Il2 to selectively expand cells with regulatory activity from a starting popula tion of mixed CD4 + T cells 94 . This observation was then confirmed for human T Reg cells 89, 95, 96 , which could be expanded selectively in vitro from both healthy donors and patients with autoimmune disease.
The suppressive activity and proliferative capacity of T Reg cells depend on TCR engagement and Il2 avail ability. Differential susceptibility to rapamycin inhi bition suggested that the TCR signalling pathway in T Reg cells differs from that of conventional T cells. The observation that T cell stimulation in the presence of rapamycin favoured upregulation of FOXP3 expression and acquisition of a regulatory phenotype 97 offered the alternative explanation that the observed increase in T Reg cell frequency after prolonged rapamycin admin istration could be due to the peripheral conversion of T cells into T Reg cells (see next section). However, our current understanding is that both explanations might be correct. mouse T Reg cells cannot activate phospholi pase Cγ and consequently generate the downstream sig nals that result in NFAT, NFκB and RAS-extracellular signalregulated kinase-AP1 activation 98 . In parallel, T Reg cells do not phosphorylate (and therefore activate) AKT in response to stimulation, and restoration of AKT activity impairs their suppressor function 99 . This has been further clarified by a report that T Reg cells express high levels of the negative PI3K regulator phosphatase and tensin homologue (PTEN) 100, 101 , the expression of which is maintained in T Reg cells after TCR stimulation (which is in contrast to conventional T cells). Targeted depletion of PTEN does not affect the suppressive capacity of T Reg cells, but it does increase their sensitiv ity to rapamycin. These data indicate that T Reg cells do not rely on the conventional PI3K-AKT-mTOR activa tion pathway and explain their lower susceptibility to rapamycinmediated inhibition.
The above observations do not clarify the mecha nism of T Reg cellspecific activation in the presence of rapamycin. It is known that the Il2R-STAT5 pathway is essential for T Reg cell homeostasis and activity 102, 103 . Furthermore, it has been reported recently that FOXP3 expression is associated with the induction of PIm2 Nature Reviews | Immunology expression 104 . Notably, PIm kinases have been impli cated in conferring T cell resistance to rapamycin mediated inhibition when STAT5signalling cytokines (including Il2) are present in adequate amounts 87 . It is therefore possible that T Reg cells can integrate TCR and Il2 signalling in a PIm2dependent pathway that allows them to progress through the cell cycle despite mTOR inhibition (FIG. 3b) .
Induction of FOXP3 expression. Natural T Reg cells arise in the thymus, but CD4
+ T cells with reg ulatory capacity can also be generated in the periphery (known as inducible T Reg cells) by antigendriven conver sion of naive T cells under certain conditions 105 . In par ticular, in vitro TCR stimulation of CD4 + CD25
-T cells in the presence of transforming growth factorβ (TGFβ) and Il2 induces FOXP3 expression. The observation that rapamycin favours this conversion has focused much attention on the involvement of mTOR in the reg ulation of FOXP3 expression (FIG. 4a) . The induction of FOXP3 expression by TGFβ depends on the activation of the transcription factor SmAD3 (mothers against decapentaplegic homologue 3) 106 , which, together with TCRinduced NFAT, binds to the enhancer region of FOXP3 and promotes chromatin remodelling that is necessary for translation. Interestingly, signalling through the AKT-mTOR pathway can inhibit activation of SmAD3 (ReF. 107) , providing an explanation for the observation that mTOR inhibition through rapamycin favours FOXP3 upregulation.
T cells with constitutively active AKT have impaired upregulation of FOXP3 in response to activation in the presence of TGFβ 77 . Interestingly, when rapamycin is present at the time of transduction of constitutively active AKT, the inhibitory effect is lost. This implies that a rapamycinsensitive signal involving AKT acti vation (and consequently, mTOR activation) is respon sible for the control of peripheral FOXP3 induction. This effect is not restricted to FOXP3 and extends to approximately 50% of the genes that are modulated in response to TGFβ 77 , which supports the view that conversion to a regulatory phenotype involves complex genetic reprogramming 78 . However, important differ ences remain between natural and inducible T Reg cells. Expression of a constitutively active form of AKT in thymocytes decreases thymic development of T Reg cells without affecting T cell ontogeny 77 , thereby confirming the ability of the AKT-mTOR pathway to prevent T Reg cell development. Expression of FOXP3 in already dif ferentiated circulating T Reg cells, however, is not affected by AKT activity, supporting the proposed model that a specific genetic programme is implemented in T Reg cells during their development.
A process of FOXP3 upregulation that is independent of TGFβ signalling has begun to be characterized (FIG. 4b) . Premature interruption of in vitro TCR and CD28 co stimulation (after 18 hours) is associated with the upreg ulation of FOXP3 expression in approximately 10% of T cells 108 . Addition of PI3K inhibitors or rapamycin after the interruption of TCR and CD28 costimulation -T cells through T cell receptor (TCR) and CD28 in the presence of transforming growth factor-β (TGFβ) promotes the transcription of FOXP3 through the cooperation of nuclear factor of activated T cells (NFAT) and sMAD3 (mothers against decapentaplegic homologue 3). This process is counteracted by the activation of mammalian target of rapamycin (mTOR), thereby explaining the increased expression of FOXP3 when stimulation takes place in the presence of rapamycin (which inhibits mTOR activation). b | Limited TCR and CD28 stimulation (<18 hours) promotes a phosphoinositide 3-kinase (PI3K)-AKT-mTOR-mediated re-organization of chromatin that includes increased accessibility to FOXP3. Prolonged TCR-CD28 stimulation (>18 hours) prevents, again through activation of the PI3K-AKT-mTOR pathway, the expression of FOXP3, which would otherwise probably be induced by signal transducer and activator of transcription 5 (sTAT5)-activating cytokines generated during the initial stimulation. This two-step model rationalizes the opposing effects of rapamycin administration during T cell activation that have been observed, which probably depend on the timing of mTOR inhibition. FKBP12, FK506-binding protein 1A, 12 kDa; IL, interleukin; IL-2R, IL-2 receptor; TGFβR, TGFβ receptor. increased this fraction to up to 75% of T cells. The effect did not involve TGFβ signalling, as neutralizing antibod ies specific for TGFβ and inhibition of SmAD kinase activity did not affect the induction of FOXP3 expression that is promoted by the inhibition of PI3K and mTOR. Interestingly, this effect was closely associated with the timing of interruption of TCR and CD28 costimulation and the addition of PI3K and mTOR inhibitors. Early addition of the inhibitors blocked the necessary T cell activation, whereas prolongation of TCR and CD28 costimulation beyond 18 hours markedly decreased FOXP3 upregulation. In addition, following the initial TCR and CD28 costimulation, histone modifications that facilitate accessibility of the FOXP3 locus to tran scription factors were observed and were subsequently lost with continuous TCR and CD28 signalling.
These findings suggest that rapamycin administra tion establishes conditions for the initiation of a two step process of FOXP3 upregulation, which is similar to that described for thymic T Reg cell development 109, 110 . In this model, TCR and CD28 signalling causes chromatin remodelling that predisposes towards the expression of FOXP3. This first step probably involves PI3K-AKTmTOR signalling, as the addition of inhibitors at the same time as TCR and CD28 stimulation prevents the necessary T cell activation. After prolonged TCR and CD28 stimulation, the accessibility of FOXP3 is then restricted in a process that involves a second round (or continuation) of PI3K-AKT-mTOR signalling. It is reasonable to imply that, by blocking the second round of signalling, the preactivated cell can then respond differently to stimulation with endogenous cytokines (such as Il2 and Il15). This promotes the activa tion of the STAT5 pathway, which is involved in both intrathymic T Reg cell development and the modulation of FOXP3 expression in peripheral T cells 102, 103, 111 . This model of FOXP3 induction might explain the recent observation that a combination of histone deacetylase inhibition and rapamycin increases the number of FOXP3 + T Reg cells in vivo 112 . On the whole, these observations delineate differences between conventional T cells and T Reg cells that shed light on previously unappreciated effects of mTOR inhibition. The observation that rapamycin causes a generalized increase in the frequency of T Reg cells is now interpreted as the sum of two effects -the ability of T Reg cells to pro liferate in the presence of rapamycin and the promotion of FOXP3 expression in peripheral T cells that are then converted into modulators of immune reactivity.
Therapeutic immunosuppression
The remarkable inhibitory action of rapamycin on DCs and effector T cells, but not T Reg cells, singles out mTOR inhibition as a promising therapeutic strategy for the prevention of transplant rejection and the treatment of autoimmune disease.
Transplant tolerance. In renal transplantation, rapamy cin is a powerful antirejection agent when used judi ciously with other immunosuppressive agents. It has unique antiatherogenic and antineoplastic properties that distinguish it from other antirejection drugs and it can promote tolerance and decrease the incidence of chronic allograft nephropathy 113 . Rapamycin was used initially with cyclosporin A, but it is also effective when combined with other immunosuppressive agents. However, the effects of calcineurin inhibitors (such as cyclosporin A) and rapamycin in transplantation seem to be markedly different. In rodents, rapamycin, but not cyclosporin A, allows activationinduced cell death of the large number of alloreactive effector T cells and favours the induction of tolerance 114, 115 . In addition, rapamycin enhances the tolerancepromoting effect of costimulation blockade, whereas cyclosporin A prevents it 116, 117 . In transplant recipients, calcineurin inhibitors, but not rapamycin, decrease the proportion of CD4
+ T Reg cells, which is a potentially negative effect of these agents 93 . Recently, the use of FOXP3 reporter mice has shown that rapamycin pro motes the de novo (TGFβdependent) conversion of alloantigenspecific CD4
+ T cells to T Reg cells under tolerizing conditions, whereas cyclosporin A abrogates this process 118 . Converted T Reg cells were more resist ant to apoptosis than conventional T cells, and adoptive transfer of converted T Reg cells potently suppressed the rejection of donor, but not third party, skin grafts. The ability of rapamycin plus Il10 to induce T regulatory type 1 (T R 1) cells that mediate stable, alloantigenspecific tolerance in pancreatic islet cell transplantation has also been reported 119 . Collectively, these data provide further evidence that the differential effects of rapamycin on effector T cells and T Reg cells (both naturally occurring and inducible) favour its ability to promote tolerance and support its use in tolerancepromoting protocols.
Recent reports suggest that mTOR inhibition, together with targeting of other key molecules that are involved in immune regulation, can promote transplant tolerance in mice. CXCchemokine receptor 3 (CXCR3) and its ligands (CXCl9, CXCl10 and CXCl11) are important for effector T cell recruitment. When com bined with a subtherapeutic regimen of rapamycin, a CXCR3specific monoclonal antibody induces indefi nite (>100 day) survival of heart or islet allografts 120 . A second finding concerns the inhibition of histone deacetylase 9 and the consequent increase in FOXP3 expression, as well as the production and function of T Reg cells 112 . When histone deacetylase 9 inhibition is combined with a short course of lowdose rapamycin, permanent donorspecific T Reg celldependent heart and pancreatic islet allograft survival is achieved 112 . T Reg cells also seem to be important in mediating the tolerogenic effect of a low dose of rapamycin in combination with monoclonal antibodies specific for T cell immuno globulin domain and mucin domain protein 1 (TIm1), which is associated with a T H 1 to T H 2type cytokine switch in experimental heart transplantation 121 .
Tolerogenic cell therapy in transplantation. The capac ity of rapamycin to deplete effector T cells but spare the growth and function of T Reg cells can be exploited in the design of new and safe protocols for cell therapy of allo graft rejection and other T cellmediated conditions.
IPEX
A rare human disease that is linked to dysfunction of the transcriptional factor forkhead box P3 (FOXP3) and that is characterized by the development of autoimmunity.
Rapamycintreated antigenpresenting cells are poor stimulators of allogeneic CD4 + effector T cell prolif eration, but enrich for potent CD4 + CD25 + FOXP3 + T Reg cells 36 . When rapamycinconditioned mouse DCs are pulsed with donor alloantigen and are then adoptively transferred to organ allograft recipients in combination with a short postoperative course of lowdose rapamycin, they induce indefinite (>100 day) graft survival 36 . Also, rapamycinconditioned recipient DCs inhibit GVHD after allogeneic haematopoietic cell transplantation, which is consistent with their tolerogenic phenotype 60 . CCR5, CCR7 and CD62l expression on rapamycin conditioned DCs is not affected by mTOR inhibition, which allows them to traffic to secondary lymphoid tissues, where their immunoregulatory function is required [59] [60] [61] . Such observations might, in part, explain the beneficial effects of rapamycin on the incidence of GVHD after haematopoietic cell transplantation that were recently reported in clinical trials 122, 123 . As an example of an alternative strategy, alloantigenspecific T Reg cells induce indefinite graft survival and T cell anergy when expanded in vitro in response to immature allogeneic DCs and then infused into rapamycinconditioned heart allograft recipients in the absence of T cell depletion 124 .
Autoimmune disease. There are numerous reports that mTOR inhibition can suppress experimental autoim mune diseases, in particular type 1 diabetes, nephritis associated with systemic lupus erythematosus (SlE) and adjuvant arthritis 125 . Rapamycin combined with Il10 blocks the incidence of type 1 diabetes and induces longterm tolerance without chronic immunosuppres sion in nonobese diabetic (NOD) mice 126 . In this model, rapamycin mediates the accumulation of suppressive FOXP3 + T Reg cells in the pancreas and prevents diabetes. By contrast, when rapamycin is combined with a CD3 specific antibody, it has a detrimental effect on disease outcome in NOD mice 127 . As discussed by the authors of this study, rapamycin might interfere with the ability of the CD3specific antibody to restore Il2 production (which is defective in NOD mice), and thus might pre vent this cytokine from maintaining tolerance in these animals. In patients with type 1 diabetes, rapamycin promotes the ex vivo proliferation of functional FOXP3 + T Reg cells 89 . moreover, naturally occurring T Reg cells from patients with type 1 diabetes treated solely with rapamy cin have a restored ability to suppress the proliferation of CD4 + CD25 -effector T cells compared with T Reg cells that have not been treated 128 . In NZB × NZW F1 female mice (a mouse model of SlE), administration of rapamycin (from 12-37 weeks of age) decreases the production of autoantibodies, glomerular deposits of immunoglobulins and the development of proteinuria, and prolongs survival 129 . Also in this model, rapamycin attenuates the severity of established nephritis through reduced lymphoproliferation, decreased CCl5 expres sion and decreased infiltration of lymphocytes into the kidneys 130 . Rapamycin is also effective for the treatment of autoimmune hepatitis following human liver trans plantation 131 and has recently been used to treat a case of refractory Crohn's disease 132 . Interestingly, rapamycin might be a clinically effective and safe therapeutic option in patients with IPeX (immunodysregulation, polyendo crinopathy and enteropathy, Xlinked syndrome) and IPEXlike disease 133 , who do not have naturally occur ring FOXP3 + T Reg cells and therefore suffer from severe autoimmune disease.
Conclusions
In summary, although the importance of mTORC1 in the regulation of innate and adaptive immune responses is now wellrecognized, the role of mTORC2 has yet to be clarified. New evidence that mTOR regulates cytokine production by antigenpresenting cells in response to inflammatory stimuli suggests a pivotal role for this mol ecule in determining the nature of T cell responses. The mechanisms by which rapamycin suppresses immune responses have been expanded from inhibition of T cell proliferation to blockade of DC maturation and support of T Reg cells, including their de novo induction. Ongoing and future areas of enquiry, which are likely to further elucidate the role of mTOR in the regulation of immune responses and tolerance, include the investigation of the role of the newly identified mTOR-survivin-aurora B complex in the activation of T cells (and other immune cells, including DCs) and the clarification of the role of PIm1 and PIm2 in determining T Reg cell resistance to mTOR inhibition. In addition, it will be important to elucidate the TGFβdependent and TGFβindependent mechanisms of FOXP3 upregulation and to clarify the physiological role of each mechanism, which will be relevant to therapeutic applications as they are both affected by mTOR modulation. Insight is also needed into the role of mTOR in memory T cells.
